Johnson & Johnson Reports Q1 2022 Results : vimarsana.com

Total sales growth of 5.0% to $23.4 Billion with operational growth of 7.7%* and adjusted operational growth of 7.9%* Earnings per share of $1.93 decreasing 16....

Related Keywords

China , Ukraine , Joaquin Duato , Prnewswire Johnson , Interventional Solutions , Exchange Commission , Skin Health Beauty , Consumer Health Company , Consumer Health , Johnson , Company Consumer Health , Chief Executive , Medical Devices , Skin Health , General Surgery , Advanced Surgery , Current Reports , Quarterly Reports , Annual Reports , First Cell Therapy , Refractory Multiple , Use Every Two Months , Only Long Acting , Only Complete Long Acting Injectable , Streamlined Process , Submits Marketing Authorisation Application , European Medicines Agency Seeking Approval , Bispecific Antibody Teclistamab , Seeks Approval , New Indication , Untreated Mantle Cell , Presents New Data Demonstrating , First Line Therapy , Mutated Metastatic Castration Resistant Prostate , Johnson Statement , Nationwide Opioid Settlement , Puy Synthes Further Reimagines Knee Restoration , Two New Innovations , Initiates First Of Its Kind Clinical Study , Bridge Critical Gaps , Severe Plaque , Adjusted Operational Sales , Operational Sales , Estimated Reported , Euro Average Rate , Private Securities Litigation Reform Act , New Consumer Health Company , Annual Report , Note Regarding Forward Looking , Consolidated Statement , Millions Except Per Share Figures , Millions Except Per Share Data , Asset Amortization , Net Earnings , Medical Device Regulation , European Medical Devices Directive , Johnson Amp ,